Clinical trials: Advanced Solid Malignancy
Tumors
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.
- Trial name
- NCT00264004
- Testing
- AZD2171
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 119 people
- Sponsor
- AstraZeneca
Neoplasms
Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous docetaxel in cancer patients with advanced solid…
- Trial name
- NCT00040547
- Testing
- Farnesyl Protein Transferase Inhibitor
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, NSCLC
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
- Trial name
- NCT06816108
- Testing
- ONO-7428
- Where
- 15 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Solid Tumor
A Study of EOC237 in Patients With Advanced Solid Tumor
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
- Trial name
- NCT05895825
- Testing
- EOC237
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Cancer, Lymphoma
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
- Trial name
- NCT00475917
- Testing
- XL844, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Exelixis
Advanced Solid Tumors
A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in combination with other antitumor therapies in patients with…
- Trial name
- NCT06092268
- Testing
- SHR-A2009 for injection ； Almonertinib Mesilate Tablets, SHR-A2009 for injection；Adebrelimab Injection
- Volunteers
- 270 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Neoplasms
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe.
- Trial name
- NCT00091585
- Testing
- SNS-595
- Where
- 4 sites in United States
- Sponsor
- Sunesis Pharmaceuticals
Malignant Solid Tumor
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
This is a phase 1 open label, 4 treatment, 4 sequence and 4 period crossover study in subjects with solid tumours no longer responding to, or eligible for standard therapies, and for whom there are no additional standard…
- Trial name
- IVIVC (NCT03553108)
- Testing
- Olaparib Treatment A, Olaparib Treatment B, Olaparib Treatment C
- Where
- 3 sites in Belgium
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Solid Tumors
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
This study designed as a multicenter, open label, two-step study to determine the optimum dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally advanced or metastatic solid tumors.
- Trial name
- NCT04261413
- Testing
- RS-0139
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
This phase I study will determine the pharmacokinetic profile of patupilone in patients with mild or moderately impaired hepatic function within 2 cycles of treatment.
- Trial name
- NCT00420524
- Testing
- Patupilone/EPO906
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT05554380
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 209 sites in United States, Puerto Rico
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent or Metastatic, Advanced Solid Tumors
Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors
A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Subjects with Recurrent or Metastatic，Advanced Solid Tumors
- Trial name
- NCT06292858
- Testing
- IMB071703 injection
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Beijng Immunoah Pharma Tech Co., Ltd.
Advanced Solid Tumour
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
- Trial name
- NCT07331155
- Testing
- LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
The proposed investigation is a Phase 1 trial to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of pioglitazone ( and carboplatin patients with advanced or metastatic solid malignancies.
- Trial name
- NCT02133625
- Testing
- carboplatin, pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Non-Small-Cell Lung, Neoplasms
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
The study is primarily designed to assess the safety and tolerability of escalating oral doses of Debio 1143 and preliminary anti-tumour activity when combined with the standard dose of avelumab in participants with advanced…
- Trial name
- NCT03270176
- Testing
- Debio 1143, Avelumab
- Where
- 9 sites in Canada, Poland and 1 more
- Volunteers
- 54 people
- Sponsor
- Debiopharm International SA
Unspecified Adult Solid Tumor, Protocol Specific
Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of alvocidib in treating patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT00112684
- Testing
- alvocidib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule.
- Trial name
- NCT00730821
- Testing
- BIBW 2992, BIBF 1120
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Myeloid Malignancies, Acute Lymphocytic Leukemia
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute…
- Conditions
- Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
- Trial name
- NCT05775406
- Testing
- KT-253
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kymera Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.